[HTML] cell.comFull View

[HTML][HTML] KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

W Liao, MJ Overman, AT Boutin, X Shang, DI Zhao… - Cancer cell, 2019 - cell.com
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …
被引用次数：459 相关文章
[HTML] sciencedirect.com

[HTML][HTML] KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

W Liao, MJ Overman, AT Boutin, X Shang, D Zhao… - Cancer Cell, 2019 - Elsevier
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …

[引用][C] KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

W Liao, MJ Overman, AT Boutin, X Shang, D Zhao… - Cancer Cell, 2019 - cir.nii.ac.jp
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal
Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
[HTML] nih.gov

[HTML][HTML] KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

W Liao, MJ Overman, AT Boutin, X Shang, D Zhao… - Cancer cell, 2019 - ncbi.nlm.nih.gov
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS*) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

W Liao, MJ Overman, AT Boutin, X Shang… - Cancer …, 2019 - mdanderson.elsevierpure.com
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

W Liao, MJ Overman, AT Boutin, X Shang… - Cancer …, 2019 - scholars.northwestern.edu
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

W Liao, MJ Overman, AT Boutin, X Shang… - Cancer …, 2019 - mahidol.elsevierpure.com
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

W Liao, MJ Overman, AT Boutin, X Shang… - Cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.

W Liao, MJ Overman, AT Boutin, X Shang, D Zhao… - Cancer Cell, 2019 - europepmc.org
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS*) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …
[PDF] rbind.io

[PDF][PDF] KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

W Liao, MJ Overman, AT Boutin… - Cancer …, 2019 - divingintogeneticsandgenomics …
The biological functions and mechanisms of oncogenic KRASG12D (KRAS*) in resistance to
immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …